source
- Novartis' Lutathera radioligand therapy may soon face first generic challengerNovartis has built a sizable business delivering radioligand therapies, with Lutathera being a leading product. A rival company is preparing to launch the first generic version, which could introd…
- Roche eyes up to $9 billion annual sales from breast cancer pill and obesity drug pipeline amid biosimilar pressureRoche reported first‑quarter earnings that showed a 5% dip in reported revenue, driven by a weaker U.S. dollar against the Swiss franc. On a constant‑currency basis, sales rose 6% to 14.7 billion S…